BACKGROUND:Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy. A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the risk of resistance. We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance. METHODS:HIV-infected pregnant Thai women with a CD4 cell count >250 cells/μL, most receivingzidovudine, were randomized at 28-38 weeks gestation to receive 1 of 3 intrapartum and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1 for 30 days. The incidence of NVP resistance mutations at day 10 or week 6 post partum in each arm was compared with that of a historical comparison group who received prenatal zidovudine and SD-NVP. NVP resistance was identified by consensus sequencing and a sensitive oligonucleotide ligation assay (OLA). RESULTS: At entry, the 169 participants had a median CD4 cell count of 456 cells/μL and an HIV load of 3.49 log(10) copies/mL. The incidence of mutations in each of the 3 P1032 arms was 0% by sequencing and 1.8%, 7.1%, and 5.3% by OLA in arms A, B, and C, respectively, compared with 13.4% by sequencing and 29.4% by OLA in the comparison group (P < .001 for each study arm vs comparison group). Grade 4 anemia developed in 1 woman. CONCLUSIONS: A 7-day tail of highly active combination therapy or 1 month of dual therapy after SD-NVP prevents most NVP resistance to minimal toxicity. CLINICAL TRIALS REGISTRATION: The IMPAACT P1032 Clinical Trial is NCT00109590, and the PHPT-2 Clinical Trial is NCT00398684.
RCT Entities:
BACKGROUND: Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy. A 1-week "tail" of lamivudine and zidovudine after SD-NVP decreases the risk of resistance. We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance. METHODS:HIV-infected pregnant Thai women with a CD4 cell count >250 cells/μL, most receiving zidovudine, were randomized at 28-38 weeks gestation to receive 1 of 3 intrapartum and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1 for 30 days. The incidence of NVP resistance mutations at day 10 or week 6 post partum in each arm was compared with that of a historical comparison group who received prenatal zidovudine and SD-NVP. NVP resistance was identified by consensus sequencing and a sensitive oligonucleotide ligation assay (OLA). RESULTS: At entry, the 169 participants had a median CD4 cell count of 456 cells/μL and an HIV load of 3.49 log(10) copies/mL. The incidence of mutations in each of the 3 P1032 arms was 0% by sequencing and 1.8%, 7.1%, and 5.3% by OLA in arms A, B, and C, respectively, compared with 13.4% by sequencing and 29.4% by OLA in the comparison group (P < .001 for each study arm vs comparison group). Grade 4 anemia developed in 1 woman. CONCLUSIONS: A 7-day tail of highly active combination therapy or 1 month of dual therapy after SD-NVP prevents most NVP resistance to minimal toxicity. CLINICAL TRIALS REGISTRATION: The IMPAACT P1032 Clinical Trial is NCT00109590, and the PHPT-2 Clinical Trial is NCT00398684.
Authors: Susan H Eshleman; Laura A Guay; Anthony Mwatha; Elizabeth R Brown; Shawn P Cunningham; Philippa Musoke; Francis Mmiro; J Brooks Jackson Journal: J Acquir Immune Defic Syndr Date: 2004-02-01 Impact factor: 3.731
Authors: L Mandelbrot; A Landreau-Mascaro; C Rekacewicz; A Berrebi; J L Bénifla; M Burgard; E Lachassine; B Barret; M L Chaix; A Bongain; N Ciraru-Vigneron; C Crenn-Hébert; J F Delfraissy; C Rouzioux; M J Mayaux; S Blanche Journal: JAMA Date: 2001-04-25 Impact factor: 56.272
Authors: Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier Journal: N Engl J Med Date: 2010-10-14 Impact factor: 91.245
Authors: Giovanina M Ellis; Madhumita Mahalanabis; Ingrid A Beck; Gregory Pepper; Amy Wright; Shannon Hamilton; Sarah Holte; Willscott E Naugler; Diane M Pawluk; Chung-Chen Li; Lisa M Frenkel Journal: J Clin Microbiol Date: 2004-08 Impact factor: 5.948
Authors: Mary A Vogler; Laura M Smeaton; Rodney L Wright; Sandra W Cardoso; Jorge Sanchez; Rosa Infante; Laura E Moran; Catherine Godfrey; Lisa M Demeter; Victoria A Johnson Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Horacio A Duarte; Ingrid A Beck; Molly Levine; Catherine Kiptinness; James M Kingoo; Bhavna Chohan; Samah R Sakr; Michael H Chung; Lisa M Frenkel Journal: AIDS Date: 2018-10-23 Impact factor: 4.177
Authors: Scott C Olson; Nicole Ngo-Giang-Huong; Ingrid Beck; Wenjie Deng; Paula Britto; David E Shapiro; Roger E Bumgarner; James I Mullins; Russell B Van Dyke; Gonzague Jourdain; Lisa M Frenkel Journal: AIDS Date: 2015-07-31 Impact factor: 4.177
Authors: Deborah K McMahon; Lu Zheng; Jane Hitti; Ellen S Chan; Elias K Halvas; Feiyu Hong; Joseph Kabanda; Frank Taulo; Nagalingeswaran Kumarasamy; Jerry Bonhomme; Carole L Wallis; Karin L Klingman; Michael D Hughes; John W Mellors Journal: Clin Infect Dis Date: 2013-01-08 Impact factor: 9.079